相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades
Margaret A. Tucker et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma
Jason Chesney et al.
MELANOMA RESEARCH (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination
Amelie Aboudaram et al.
MELANOMA RESEARCH (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation
Luke R. G. Pike et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: a Systematic Review
Charissa A. C. Jessurun et al.
FRONTIERS IN ONCOLOGY (2017)
Adoptive Cell Therapy for Metastatic Melanoma
Efrat Merhavi-Shoham et al.
CANCER JOURNAL (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
The global burden of melanoma: results from the Global Burden of Disease Study 2015
C. Karimkhani et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
J. H. Lee et al.
ANNALS OF ONCOLOGY (2017)
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
Matteo S. Carlino et al.
BRITISH JOURNAL OF CANCER (2016)
The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
Alexander N. Shoushtari et al.
CANCER (2016)
Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
Alain P. Algazi et al.
CANCER (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Georgina V. Long et al.
LANCET ONCOLOGY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
Yoshio Nakamura et al.
ONCOTARGET (2016)
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials
Jean Jacques Grob et al.
LANCET ONCOLOGY (2015)
Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
Henrike Tolk et al.
MELANOMA RESEARCH (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
David R. Minor et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
Siwen Hu-Lieskovan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Lise Boussemart et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Therapeutic vaccines for cancer: an overview of clinical trials
Ignacio Melero et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Matthew D. Vesely et al.
RENAISSANCE OF CANCER IMMUNOTHERAPY (2013)
Clinical Activity of Ipilimumab for Metastatic Uveal Melanoma
Jason J. Luke et al.
CANCER (2013)
Patterns of Onset and Resolution of Immune-Related Adverse Events of Special Interest With Ipilimumab Detailed Safety Analysis From a Phase 3 Trial in Patients With Advanced Melanoma
Jeffrey S. Weber et al.
CANCER (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Ipilimumab for Patients With Advanced Mucosal Melanoma
Michael A. Postow et al.
ONCOLOGIST (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Prognostic Factors for Survival in Melanoma Patients With Brain Metastases
Michael A. Davies et al.
CANCER (2011)
Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma
Yan Kong et al.
CLINICAL CANCER RESEARCH (2011)
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Lukas Baitsch et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sunburns and risk of cutaneous melanoma: Does age matter? A comprehensive meta-analysis
Leslie K. Dennis et al.
ANNALS OF EPIDEMIOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients
Maria Daniotti et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Number of Nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma
Nancy E. Thomas et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
